Related Experiment Video
Updated: Aug 8, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Who benefits from hormone therapy?
1Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
Abstract:
Not all hormone receptor (HR)-positive tumors respond to hormone therapy, although hormone therapy has brought significant benefits to breast cancer patients. In order to improve the efficacy of hormone therapy, a variety of new approaches are currently being tested in such as extended adjuvant therapy, selection of responders using array-based techniques and combination therapy with signal transduction inhibitors. It is therefore necessary to distinguish between highly hormone responsive tumors and relatively less hormone sensitive tumors. Through reviewing recent outcomes of clinical trials, these issues are summarized and discussed in this review.
Insights
Not all hormone receptor-positive tumors benefit from hormone therapy. This review discusses strategies like extended adjuvant therapy and new drug combinations to improve treatment effectiveness for breast cancer.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Hormone therapy is a cornerstone for hormone receptor (HR)-positive breast cancer, yet response varies significantly.
- Identifying non-responders is crucial for optimizing patient outcomes and avoiding ineffective treatments.
Purpose of the Study:
- To review current clinical trial outcomes regarding hormone therapy for HR-positive breast cancer.
- To discuss novel strategies aimed at enhancing hormone therapy efficacy and identifying responsive tumors.
Main Methods:
- Review of recent clinical trial data and scientific literature.
- Analysis of emerging therapeutic approaches and predictive biomarkers.
Main Results:
- Hormone therapy benefits are not universal for HR-positive tumors.
- New strategies including extended adjuvant therapy, array-based responder selection, and combination therapies show promise.
Conclusions:
- Distinguishing between highly hormone-responsive and less sensitive tumors is essential.
- Further research and clinical validation are needed to refine treatment selection and improve patient outcomes in HR-positive breast cancer.
Related Concept Videos
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Menopause
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...